Prevalence of neuromyelitis optica spectrum disorder in antioquia between 2016 and 2018

Bennett, 2015, International consensus diagnostic criteria for neuromyelitis optica spectrum disorders, Neurology, 85, 177, 10.1212/WNL.0000000000001729 Flanagan, 2014, Neuromyelitis optica spectrum disorders, Curr. Neurol. Neurosci. Rep., 14, 483, 10.1007/s11910-014-0483-3 Flanagan, 2019, Neuromyelitis optica spectrum disorder and other non–multiple sclerosis central nervous system inflammatory diseases, Contin. Lifelong Learn. Neurol., 25, 815, 10.1212/CON.0000000000000742 Huda, 2019, Neuromyelitis optica spectrum disorders, Clin. Med., 19, 169, 10.7861/clinmedicine.19-2-169 Bradl, 2018, Mechanisms for lesion localization in neuromyelitis optica spectrum disorders, Curr. Opin. Neurol., 31, 325, 10.1097/WCO.0000000000000551 Palace, 2019, Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders, Brain, 142, 1310, 10.1093/brain/awz054 Kleiter, 2018, Apheresis therapies for NMOSD attacks, Neurology, 5, e504 Romeo, 2019, Treatment of neuromyelitis optica spectrum disorders, Curr. Opin. Neurol., 31, 250 Bruscolini, 2018, Diagnosis and management of neuromyelitis optica spectrum disorders - an update, Autoimmun. Rev., 17, 195, 10.1016/j.autrev.2018.01.001 Hor, 2020, Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide, Front. Neurol., 11 Alvarenga, 2017, Epidemiology of neuromyelitis optica in Latin America, Mult. Scler. J., 3, 1 Rivera, 2008, Characteristics of Devic ’ s disease (neuromyelitis optica) in Mexico, J. Neurol., 255, 710, 10.1007/s00415-008-0781-2 Atehortúa, 2016, Prevalence of dystonia in Antioquia, Colombia, Neuroepidemiology, 46, 137, 10.1159/000443834 Sánchez, 2000, Prevalencia de la esclerosis múltiple en Colombia, Rev. Neurol., 31, 1101 Sánchez, 2002, Prevalencia de miastenia gravis en Antioquia, Colombia, Rev. Neurol., 34, 1010 Sánchez, 2004, Prevalence of Parkinson's disease and parkinsonism in a Colombian population using the capture-recapture method, Int. J. Neurosci., 114, 175, 10.1080/00207450490269444 Zapata-Zapata, 2020, Prevalence, incidence, and clinical-epidemiological characterization of amyotrophic lateral sclerosis in Antioquia: Colombia, Neuroepidemiology, 54, 251, 10.1159/000504549 DANE Departamento Administrativo Nacional de Estadística (2018). Censo General 2018 [docu- mento en línea]. Disponible en http://www.dane. gov.co/daneweb_V09/index.php?option=com_ content&view=article&id=307&Itemid=124. 2013, World medical association declaration of Helsinki: ethical principles for medical involving human subjects, JAMA, 310, 2191, 10.1001/jama.2013.281053 Colombia M de Salud. Resolución número 8430 de 1993. 1993. Chao, 2001, The applications of capture-recapture models to epidemiological data, Stat. Med., 20, 3123, 10.1002/sim.996 Reyes, 2016, Espectro de neuromielitis óptica en Colombia, primera caracterización clínico imagenológica en tres centros de Bogotá, Acta Neurol. Colomb., 32, 190, 10.22379/2422402296 Quek, 2013, Effects of age and sex on aquaporin-4 autoimmunity, Arch. Neurol., 69, 1039 De Carvalho, 2015, Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: a review, J. Neurol. Sci., 355, 7 2016, Organización Panamericana de la Salud y Consejo de Organizaciones Internacionales de las Ciencias Médica. Pautas éticas internacionales para la investigación relacionada con la salud con seres humanos, Cuarta Edición, Ginebra: Consejo de Organizaciones Internacionales de las Ciencias Médicas (CIOMS) Palace, 2021, Worldwide incidence and prevalence of NMO: a systematic review, Neurology, 96, 59 Jarius, 2020, Neuromyelitis optica, Nat. Rev. Dis. Prim., 6, 85, 10.1038/s41572-020-0214-9 Flanagan, 2016, Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum, Ann. Neurol., 79, 775, 10.1002/ana.24617 Etemadifar, 2015, Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis, Mult. Scler. Int., 2015, 1, 10.1155/2015/174720 Crout, 2016, Neuromyelitis optica (Devic ’ s syndrome): an appraisal, Curr. Rheumatol. Rep., 18, 54, 10.1007/s11926-016-0599-3 De Castillo, 2021, Epidemiological findings of neuromyelitis optica spectrum disorders in a Venezuelan study, Mult. Scler. Relat. Disord., 47 Pandit, 2015, Demographic and clinical features of neuromyelitis optica: a review, Mult. Scler. J., 21, 845, 10.1177/1352458515572406 Asgari, 2011, A population-based study of neuromyelitis optica in Caucasians, Neurology, 76, 1589, 10.1212/WNL.0b013e3182190f74 Papp, 2018, Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark, Neurology, 91, e2265, 10.1212/WNL.0000000000006645 Cossburn, 2012, The prevalence of neuromyelitis optica in South East Wales, Eur. J. Neurol., 19, 655, 10.1111/j.1468-1331.2011.03529.x Sepúlveda, 2018, Epidemiology of NMOSD in Catalonia : influence of the new 2015 criteria in incidence and prevalence estimates, Mult. Scler. J., 24, 1843, 10.1177/1352458517735191 Pandit, 2014, Prevalence and patterns of demyelinating central nervous system disorders in urban, Mult. Scler. J., 20, 1651, 10.1177/1352458514521503 Houzen, 2017, Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan, Neurology, 89, 1995, 10.1212/WNL.0000000000004611 Eskandarieh, 2017, Neuromyelitis optica spectrum disorders in Iran, Mult. Scler. Relat. Disord., 18, 209, 10.1016/j.msard.2017.10.007 Lee, 2020, Prevalence and incidence of neuromyelitis optica spectrum disorder in Korea : population based study, J. Korean Med. Sci., 35, 1, 10.3346/jkms.2020.35.e115 Bukhari, 2017, Incidence and prevalence of NMOSD in Australia and New Zealand, J. Neurol. Neurosurg. Psychiatry, 88, 632, 10.1136/jnnp-2016-314839 Cabrera-Gómez, 2009, An epidemiological study of neuromyelitis optica in Cuba, J. Neurol., 256, 35, 10.1007/s00415-009-0009-0 Lana-Peixoto, 2021, Prevalence of neuromyelitis optica spectrum disorder in Belo Horizonte, Southeast Brazil, Mult. Scler. Relat. Disord., 50, 10.1016/j.msard.2021.102807